drugset
drugset / Trial / NCT00000273

A Laboratory Model for Heroin Abuse Medications - 8

NCT00000273 ↗

Phase 2 Completed 8 enrolled New York State Psychiatric Institute National Institute on Drug Abuse (NIDA) · collab
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to evaluate the effects of treatment medications (methadone, buprenorphine, LAAM, naltrexone, naltrexone microcapsules, and methoclocinnamox) on I.V. and smoked heroin self-administration."

Timeline

Start
1995-08
Primary completion
2005-11
Completion
2005-11

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Buprenorphine Other / unclassified 0 mg/kg —
Subject Buprenorphine Other / unclassified 0.00178571 mg/kg —
Subject Buprenorphine Other / unclassified 0.00714286 mg/kg —
Subject Buprenorphine Other / unclassified 0.0285714 mg/kg —
Subject Buprenorphine Other / unclassified 0.114286 mg/kg —
Subject Fentanyl Other / unclassified 0 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.000892857 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00178571 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00267143 mg/kg Intravenous
Subject Fentanyl Other / unclassified 0.00357143 mg/kg Intravenous
Subject Morphine Other / unclassified 0 mg/kg Intravenous
Subject Morphine Other / unclassified 0.0892857 mg/kg Intravenous
Subject Morphine Other / unclassified 0.178571 mg/kg Intravenous
Subject Morphine Other / unclassified 0.357143 mg/kg Intravenous
Subject Morphine Other / unclassified 0.714286 mg/kg Intravenous
Subject Oxycodone Other / unclassified 0 mg/kg —
Subject Oxycodone Other / unclassified 0.0892857 mg/kg —
Subject Oxycodone Other / unclassified 0.178571 mg/kg —
Subject Oxycodone Other / unclassified 0.357143 mg/kg —
Subject Oxycodone Other / unclassified 0.714286 mg/kg —
Background Methadone Other / unclassified — —

Indications

heroin dependence